Bio-Engine is a new approach to power the engraftment of CAR-T without the need to prepare the patient with chemotherapy before their infusion. Our technology designs CAR-T to increase in numbers after infusion driven by the ability to be boosted by normal blood cells. Avoidance of preparative chemotherapy facilitates repeated infusions of CAR-T to improve their therapeutic potential and to reduce the costs and complexity of clinical care.
